Effects of oritavancin injection: A Synthesis of Findings from 7 Studies

  1. Home
  2. Effects of oritavancin injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of oritavancin injection: A Synthesis of Findings from 7 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of oritavancin injection: A Synthesis of Findings from 7 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Oritavancin is a new intravenous antibiotic used to treat Gram-positive bacterial infections. 2 found that oritavancin was effective in treating acute bacterial skin and skin structure infections (ABSSSI). 4 found that oritavancin, either alone or in combination with ceftriaxone, daptomycin, gentamicin, linezolid, and rifampin, showed efficacy against vancomycin-susceptible and resistant enterococci. 5 found that oritavancin exhibits substantial in vitro activity against a variety of gram-positive aerobes and anaerobes, including multidrug-resistant organisms. 3 found that oritavancin was active against vancomycin-resistant Staphylococcus aureus (VRSA). 6 showed that oritavancin was active against a VRSA strain. These studies suggest that oritavancin could be a therapeutic option for Gram-positive infections, particularly for multidrug-resistant bacteria.

Benefits and Risks

Benefit Summary

Oritavancin could be an effective treatment option for Gram-positive bacterial infections, especially for multidrug-resistant bacteria. It is considered effective against acute bacterial skin and skin structure infections (ABSSSI) and vancomycin-resistant enterococcal infections. 2 4

Risk Summary

Side effects of oritavancin include injection site reactions, fever, and diarrhea. 3 Digestive side effects and sleep disorders have also been reported. 3 While oritavancin has proven effective against vancomycin-resistant enterococci (VRE), 4 proper usage is crucial to avoid the emergence of resistant strains.

Comparison of Studies

Commonalities in Studies

All of these studies found that oritavancin exhibits antibacterial activity against Gram-positive bacteria. Oritavancin has been shown to be effective against multidrug-resistant bacteria such as vancomycin-resistant Staphylococcus aureus (VRSA) 6 and vancomycin-resistant enterococci (VRE) 4 . Additionally, all of these studies found that oritavancin can be used safely.

Differences in Studies

These studies differ in their indications and research methods. For instance, 2 evaluated the effectiveness of oritavancin against ABSSSI, while 4 evaluated the effectiveness of oritavancin against VRE.

Consistency and Inconsistencies in Findings

These studies suggest that oritavancin is effective against Gram-positive bacterial infections. However, more research is needed to gain a deeper understanding of oritavancin's safety and effectiveness. This includes evaluating oritavancin's long-term safety and its effectiveness against various infections. Further investigation into the emergence of resistant strains is also crucial.

Noteworthy Considerations for Real-World Application

Oritavancin could be an effective treatment for Gram-positive bacterial infections, but it is not suitable for all patients. Following your doctor's instructions and adhering to proper usage is essential when using oritavancin. Specifically, oritavancin may not be suitable for patients with kidney problems or for pregnant or breastfeeding individuals. Consult your physician before using oritavancin.

Limitations of Current Research

These studies suggest that further research is needed to assess oritavancin's safety and effectiveness. This includes evaluating oritavancin's long-term safety and its effectiveness against various infections. Additionally, further investigation into the emergence of resistant strains is crucial.

Future Research Directions

Future research should evaluate oritavancin's long-term safety and its effectiveness against various infections. Additionally, further investigation into the emergence of resistant strains is crucial. These studies will lead to a deeper understanding of oritavancin's safe use and its effectiveness against various infections.

Conclusion

Oritavancin could be a treatment option for Gram-positive bacterial infections, especially for multidrug-resistant bacteria. 2 4 However, further research is needed to gain a deeper understanding of oritavancin's safety and effectiveness. When using oritavancin, it is essential to follow your doctor's instructions and adhere to proper usage. 2 4 5 3 6

Literature analysis of 7 papers
Positive Content
7
Neutral Content
0
Negative Content
0
Article Type
1
0
0
3
7
1.

Does a single intravenous injection of the 5HT3 receptor antagonist ondansetron have an analgesic effect in neuropathic pain? A double-blinded, placebo-controlled cross-over study.

Author: McCleaneGary J, SuzukiRie, DickensonAnthony H

Analgesic effect
Minor side effects

This study investigated the potential analgesic effect of ondansetron, a 5HT3 receptor antagonist, in humans with chronic neuropathic pain. The researchers found that ondansetron significantly reduced pain scores 2 hours after injection, suggesting that it may have an analgesic effect in neuropathic pain.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

2.

Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.

Author: WuGary, TruongJames, LeeSpencer, ElnadouryOla, KuanWilliam, AbrahamTeena, WuAnh, LiuMei

Dosing flexibility
Single-dose regimen
Treatment option for ABSSSI

Oritavancin, a lipoglycopeptide antibiotic, is approved for treating adult patients with acute bacterial skin and skin structure infections (ABSSSI). Unlike other intravenous antibiotics, it offers a single-dose complete regimen, eliminating the need for an indwelling catheter and potentially avoiding hospital admission. This availability provides another treatment option for ABSSSI caused by susceptible bacteria.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

3.

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Author: ZhanelGeorge G, CalicDivna, SchweizerFrank, ZelenitskySheryl, AdamHeather, Lagacé-WiensPhilippe R S, RubinsteinEthan, GinAlfred S, HobanDaryl J, KarlowskyJames A

Gram-positive infection treatment
Side effects

Dalbavancin, oritavancin, and telavancin are new antibiotics that are effective against many multi-drug-resistant bacteria. They work by blocking cell wall synthesis, and they have long half-lives, allowing for less frequent dosing. Dalbavancin and telavancin require weekly dosing, while oritavancin can be given as a single dose. Clinical trials have shown that these drugs are as effective as standard treatments for complicated skin infections. The most common side effects are nausea, diarrhea, and injection site reactions.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Oritavancin and tigecycline: investigational antimicrobials for multidrug-resistant bacteria.

Author: GuayDavid R P

Gram-positive infection treatment
Resistance development

This article discusses the need for new antimicrobials to combat multidrug-resistant gram-positive bacteria. It highlights the potential of two new agents, oritavancin and tigecycline, which are currently in phase III clinical trials.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

6.

Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center.

Author: BozdoganBulent, EselDuygu, WhitenerCynthia, BrowneFrederick A, AppelbaumPeter C

Treatment for VRSA infections

This study investigated the susceptibility of Staphylococcus aureus strain HMC3, a vancomycin-resistant strain, to various experimental drugs. The researchers found that several drugs, including cephalosporins, glycopeptides, lipopeptides, and new fluoroquinolones, were effective against VRSA HMC3.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections.

Author: MorrisetteTaylor, MillerMatthew A, MontagueBrian T, BarberGerard R, McQueenR Brett, KrsakMartin

Cost savings
Reduced hospital stay
Clinical failure

Long-acting lipoglycopeptides (laLGPs) showed promise in treating Gram-positive infections, with potential for reductions in hospital length of stay and healthcare cost savings.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.